AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...

AbbVie stock surged early Friday after beating fourth-quarter expectations, largely on the back of its immunology drugs.

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq ...

AbbVie (ABBV) is expected to beat Q4 earnings estimates with strong performance from key products, including Skyrizi and ...

Quarterly sales of Humira declined 49% to $1.68 billion, a steeper fall than the $1.99 billion analysts expected, according ...

AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid ...

Key Takeaways AbbVie's fourth-quarter revenue exceeded forecasts on higher sales of its Skyrizi and Rinvoq drugs to treat ...

AbbVie saw fourth-quarter sales handily beat Wall Street's projections as gains from its newer anti-inflammatory drugs helped offset declines from Humira, once its best performing asset. The drugmaker ...

AbbVie (NYSE:ABBV) saw its shares jump more than 4% in premarket trading Friday after the company's profit guidance for the fiscal 2025 year exceeded analyst expectations, driven by strong sales in ...

The North Chicago-based drugmaker is relying on newer treatments to make up for falling sales of Humira, its aging ...

Says well-positioned with ex-Humira platform for 2025. Sees clear runway for growth “for at least eight years.” Expects Skyrizi and Rinvoq to ...

AbbVie (ABBV) is reaffirming its expectations for a high single-digit compound annual revenue growth rate through 2029. This guidance assumes ...